Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Completed · Phase 4

Conditions studied: Acute Pseudophakic Cystoid Macular Edema

In brief

To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.

Key facts

Study ID

NCT00595543

Run by

Bp Consulting, Inc

People needed

166

Starts

2008-01-01

Expected to finish

2009-03-01

Last updated by the study team

2009-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract surgery
• Males and females 18 years and older
• Able to provide written informed consent

You may not qualify if…

• Complicated cataract surgery, particularly posterior capsule rupture and vitreous loss
• Pre-Existing macular pathology, including macular edema, macular scar, macular hole, or macular pucker
• History of Uveitis
• Ipsilateral intraocular surgery prior to cataract surgery
• CME greater than one year duration

Where it is running

• Soll Eye Associates — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.